Glycopyrrolate/formoterol fumarate vs Umeclidinium

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Chronic Obstructive Pulmonary Disease

Shared mechanism: Muscarinic acetylcholine receptor (M3) · full Chronic Obstructive Pulmonary Disease pipeline

Glycopyrrolate/formoterol fumarate · Bevespi Aerosphere

Marketed by AstraZeneca

Approved in Chronic Obstructive Pulmonary Diseasesmall molecule combination
Weak signal

NCT03324607 · Phase 2/3 · completed

The study used a single treatment group without randomization, blinding, or a placebo or active comparator, and only 17 participants contributed to the primary imaging analysis. Its primary endpoints were surrogate MRI measures rather than established clinical outcomes, and the findings were mixed across those measures, so they provide limited evidence about Bevespi’s clinical effectiveness.

Reported efficacy

Ventilation Distribution as Measured by Ventilation Defect+Low Percent (Week 2); Barrier Uptake. (2 weeks); Red Blood Cell (RBC) Uptake (2 weeks): Ventilation Distribution as Measured by Ventilation Defect+Low Percent (Week 2): Treatment — Baseline: 57.8 percentage of total ventilation (Standard Deviation 8.4); Week 2: 52.5 percentage of total ventilation (Standard Deviation 10.6) (mixed)

Result source: NCT03324607

Umeclidinium · Incruse Ellipta

Marketed by GlaxoSmithKline

Approved in Chronic Obstructive Pulmonary Diseasesmall molecule
Reliable signal

NCT02184611 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled trial in 308 patients using lung function (trough FEV1) as its primary measure, and umeclidinium produced a significantly greater improvement than placebo (least-squares mean difference 0.154 L, 95% CI 0.113 to 0.194, p<0.001).

Reported efficacy

Change From Baseline in Trough (Pre-bronchodilator) Forced Expiratory Volume in 1 Second (FEV1) on Treatment Day 169 (Baseline (Day 1) and Day 169): Change from baseline in trough FEV1 at Day 169 (primary endpoint): UMEC 62.5 mcg vs placebo, LS mean treatment difference 154 mL (95% CI 113, 194; p<0.001) (met)

Result source: NCT02184611

Results for Chronic Obstructive Pulmonary Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointGlycopyrrolate/​formoterol fumarateUmeclidinium
Moderate or severe exacerbations, annualised rate—Not reported—Trial running · NCT06474039
Trough FEV1, change—Not reported0.1 vs -0.0+0.2 vs placebo62.5 mcg · wk 24 · n 176NCT02184611
21 other results
  • 0.1 vs -0.0 62.5 µg · wk 12.14 · n 195 · Phase 3 · primary NCT01957163
  • 0.1 vs -0.0 125 µg QD · wk 12.14 · n 183 · Phase 3 · primary NCT01772147
  • 0.1 vs -0.0 125 µg · wk 12.14 · n 188 · Phase 3 · primary NCT01957163
  • 0.1 vs -0.0 125 µg QD · wk 12 · n 184 · Phase 3 · primary NCT01772134
  • 0.1 vs -0.0 62.5 µg QD · wk 12.14 · n 178 · Phase 3 · primary NCT01772147
  • 0.1 vs -0.0 62.5 µg QD · wk 12 · n 190 · Phase 3 · primary NCT01772134
  • 0.1 vs -0.0 125 µg · wk 12.14 · n 199 · Phase 3 · primary NCT02119286
  • 0.1 vs -0.0 62.5 µg · wk 12.14 · n 195 · Phase 3 · primary NCT02119286
  • 0.2 vs 0.1 62.5 mcg QD · wk 12.14 · n 392 · Phase 3 · primary NCT02207829
  • 0.2 vs 0.2 62.5/25 µg · wk 12.14 · n 392 · Phase 3 · primary NCT02257385
  • 0.1 vs 0.1 100/62.5/25 · wk 24 · n 307 · Phase 3 · primary NCT02729051
  • 0.2 vs 0.0 62.5/25 mcg · wk 12 · n 227 · Phase 3 · secondary NCT02152605
  • 0.2 vs 0.1 62.5/25 mcg · wk 12.14 · n 349 · Phase 3 · secondary NCT01879410
  • 0.1 vs -0.0 62.5 mcg+ICS/LABA · wk 12 · n 109 · Phase 4 · primary NCT02257372
  • 0.1 vs -0.0 62.5/25 mcg · wk 24 · n 691 · Phase 4 · primary NCT03034915
  • 0.1 vs 0.1 62.5 mcg QD · wk 12 · n 431 · Phase 4 · primary NCT02236611
  • 0.1 vs 0.1 100/250 µg · wk 4 · n 81 · Phase 2 · primary NCT02164539
  • 0.2 vs 0.1 100/125 µg · wk 4 · n 44 · Phase 2 · primary NCT02164539
  • 0.1 vs 0.1 100/15.6 µg · wk 4 · n 42 · Phase 2 · primary NCT02164539
  • 0.2 vs 0.1 100/62.5 µg · wk 4 · n 39 · Phase 2 · primary NCT02164539
  • 0.2 vs -0.0 62.5/25 mcg · wk 12 · n 175 · Phase 4 · secondary NCT02275052
SGRQ total, change—Not reported-6.2 vs -2.1−4 vs placebo62.5/25 mcg · wk 12 · n 212NCT02152605
5 other results
  • -7.3 vs -4.3 62.5 mcg · wk 24 · n 205 · Phase 3 · secondary NCT02184611
  • -7.0 vs -2.5 62.5 mcg · wk 12 · n 205 · Phase 3 · secondary NCT02184611
  • -5.8 vs -1.4 62.5 mcg · wk 4 · n 205 · Phase 3 · secondary NCT02184611
  • -5.8 vs -4.9 100/62.5/25 · wk 24 · n 489 · Phase 3 · secondary NCT02729051
  • -5.0 vs -3.3 62.5/25 mcg · wk 24 · n 704 · Phase 4 · secondary NCT03034915
TDI focal score—Not reported2.5 vs 1.6+0.9 vs placebo62.5 mcg · wk 24 · n 176NCT02184611

Moderate or severe exacerbations, annualised rate

Glycopyrrolate/​formoterol fumarate
—Not reported
Umeclidinium
—Trial running · NCT06474039

Trough FEV1, change

Glycopyrrolate/​formoterol fumarate
—Not reported
Umeclidinium
0.1 vs -0.0+0.2 vs placebo62.5 mcg · wk 24 · n 176NCT02184611
21 other results
  • 0.1 vs -0.0 62.5 µg · wk 12.14 · n 195 · Phase 3 · primary NCT01957163
  • 0.1 vs -0.0 125 µg QD · wk 12.14 · n 183 · Phase 3 · primary NCT01772147
  • 0.1 vs -0.0 125 µg · wk 12.14 · n 188 · Phase 3 · primary NCT01957163
  • 0.1 vs -0.0 125 µg QD · wk 12 · n 184 · Phase 3 · primary NCT01772134
  • 0.1 vs -0.0 62.5 µg QD · wk 12.14 · n 178 · Phase 3 · primary NCT01772147
  • 0.1 vs -0.0 62.5 µg QD · wk 12 · n 190 · Phase 3 · primary NCT01772134
  • 0.1 vs -0.0 125 µg · wk 12.14 · n 199 · Phase 3 · primary NCT02119286
  • 0.1 vs -0.0 62.5 µg · wk 12.14 · n 195 · Phase 3 · primary NCT02119286
  • 0.2 vs 0.1 62.5 mcg QD · wk 12.14 · n 392 · Phase 3 · primary NCT02207829
  • 0.2 vs 0.2 62.5/25 µg · wk 12.14 · n 392 · Phase 3 · primary NCT02257385
  • 0.1 vs 0.1 100/62.5/25 · wk 24 · n 307 · Phase 3 · primary NCT02729051
  • 0.2 vs 0.0 62.5/25 mcg · wk 12 · n 227 · Phase 3 · secondary NCT02152605
  • 0.2 vs 0.1 62.5/25 mcg · wk 12.14 · n 349 · Phase 3 · secondary NCT01879410
  • 0.1 vs -0.0 62.5 mcg+ICS/LABA · wk 12 · n 109 · Phase 4 · primary NCT02257372
  • 0.1 vs -0.0 62.5/25 mcg · wk 24 · n 691 · Phase 4 · primary NCT03034915
  • 0.1 vs 0.1 62.5 mcg QD · wk 12 · n 431 · Phase 4 · primary NCT02236611
  • 0.1 vs 0.1 100/250 µg · wk 4 · n 81 · Phase 2 · primary NCT02164539
  • 0.2 vs 0.1 100/125 µg · wk 4 · n 44 · Phase 2 · primary NCT02164539
  • 0.1 vs 0.1 100/15.6 µg · wk 4 · n 42 · Phase 2 · primary NCT02164539
  • 0.2 vs 0.1 100/62.5 µg · wk 4 · n 39 · Phase 2 · primary NCT02164539
  • 0.2 vs -0.0 62.5/25 mcg · wk 12 · n 175 · Phase 4 · secondary NCT02275052

SGRQ total, change

Glycopyrrolate/​formoterol fumarate
—Not reported
Umeclidinium
-6.2 vs -2.1−4 vs placebo62.5/25 mcg · wk 12 · n 212NCT02152605
5 other results
  • -7.3 vs -4.3 62.5 mcg · wk 24 · n 205 · Phase 3 · secondary NCT02184611
  • -7.0 vs -2.5 62.5 mcg · wk 12 · n 205 · Phase 3 · secondary NCT02184611
  • -5.8 vs -1.4 62.5 mcg · wk 4 · n 205 · Phase 3 · secondary NCT02184611
  • -5.8 vs -4.9 100/62.5/25 · wk 24 · n 489 · Phase 3 · secondary NCT02729051
  • -5.0 vs -3.3 62.5/25 mcg · wk 24 · n 704 · Phase 4 · secondary NCT03034915

TDI focal score

Glycopyrrolate/​formoterol fumarate
—Not reported
Umeclidinium
2.5 vs 1.6+0.9 vs placebo62.5 mcg · wk 24 · n 176NCT02184611
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety

Coverage. Glycopyrrolate/formoterol fumarate: 3 of 5 rows · Umeclidinium: 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricGlycopyrrolate/​formoterol fumarateUmeclidinium
Exercise Endurance Time Seconds
absolute value · seconds
382.5 vs 328 placebo secondsa,b,c
NCT03081156 · Phase 4 · registry result, not featured evidence
-2.06 vs -5.37 placebo seconds @ 12wk62.5/25 mcga,b,c
NCT02275052 · Phase 4 · registry result, not featured evidence
Dropout rate
0%d
NCT03324607 · Phase 2/3 · combination · Chronic Obstructive Pulmonary Disease · phase 2/3
show 1 more result
—
NCT03081156 · Phase 4 · registry result, not featured evidence
13.7%62.5 mcge
NCT02184611 · Phase 3
show 25 more results
8.9%125 µg QD
NCT01772147 · Phase 3 · combination
12.3%62.5 µg QD
NCT01772147 · Phase 3 · combination
5.3%62.5 µg
NCT01957163 · Phase 3 · combination
8.7%125 µg
NCT01957163 · Phase 3 · combination
3.4%125 µg
NCT02119286 · Phase 3 · combination
5.3%62.5 µg
NCT02119286 · Phase 3 · combination
10.7%125 µg QD
NCT01772134 · Phase 3 · combination
6.9%62.5 µg QD
NCT01772134 · Phase 3 · combination
11.7%62.5/25 mcg
NCT03034915 · Phase 4 · registry result, not featured evidence
—62.5/25 mcg
NCT02275052 · Phase 4 · registry result, not featured evidence
5%62.5 mcg QD
NCT02236611 · Phase 4 · registry result, not featured evidence
8.4%62.5 mcg+ICS/LABA
NCT02257372 · Phase 4 · registry result, not featured evidence · combination
5.7%100/62.5/25
NCT02729051 · Phase 3 · registry result, not featured evidence
8.3%62.5 mcg QD
NCT02207829 · Phase 3 · registry result, not featured evidence
4.6%62.5/25 µg
NCT02257385 · Phase 3 · registry result, not featured evidence
7.3%62.5/25 mcg
NCT02152605 · Phase 3 · registry result, not featured evidence
—62.5/25mcg
NCT02152605 · Phase 3 · registry result, not featured evidence
—62.5/25 mcg
NCT01879410 · Phase 3 · registry result, not featured evidence
—62.5/25 µg
NCT02014480 · Phase 3 · registry result, not featured evidence
—62.5/25 µg once daily
NCT01716520 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3
3.5%100/250 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
4.3%100/125 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0%100/15.6 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
2.5%100/62.5 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
—100/250/25 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
Discontinued due to AEs
—d
NCT03324607 · Phase 2/3 · combination · Chronic Obstructive Pulmonary Disease · phase 2/3
show 1 more result
—
NCT03081156 · Phase 4 · registry result, not featured evidence
2.4%62.5 mcge
NCT02184611 · Phase 3
show 25 more results
3%125 µg QD
NCT01772147 · Phase 3 · combination
4.9%62.5 µg QD
NCT01772147 · Phase 3 · combination
1%62.5 µg
NCT01957163 · Phase 3 · combination
1.9%125 µg
NCT01957163 · Phase 3 · combination
1%125 µg
NCT02119286 · Phase 3 · combination
3.4%62.5 µg
NCT02119286 · Phase 3 · combination
4.9%125 µg QD
NCT01772134 · Phase 3 · combination
2.5%62.5 µg QD
NCT01772134 · Phase 3 · combination
3.6%62.5/25 mcg
NCT03034915 · Phase 4 · registry result, not featured evidence
—62.5/25 mcg
NCT02275052 · Phase 4 · registry result, not featured evidence
1.9%62.5 mcg QD
NCT02236611 · Phase 4 · registry result, not featured evidence
5.9%62.5 mcg+ICS/LABA
NCT02257372 · Phase 4 · registry result, not featured evidence · combination
4%100/62.5/25
NCT02729051 · Phase 3 · registry result, not featured evidence
2%62.5 mcg QD
NCT02207829 · Phase 3 · registry result, not featured evidence
2.5%62.5/25 µg
NCT02257385 · Phase 3 · registry result, not featured evidence
3.2%62.5/25 mcg
NCT02152605 · Phase 3 · registry result, not featured evidence
—62.5/25mcg
NCT02152605 · Phase 3 · registry result, not featured evidence
—62.5/25 mcg
NCT01879410 · Phase 3 · registry result, not featured evidence
—62.5/25 µg
NCT02014480 · Phase 3 · registry result, not featured evidence
—62.5/25 µg once daily
NCT01716520 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3
—100/250 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
—100/125 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
—100/15.6 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
—100/62.5 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
—100/250/25 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
Serious AEs
0%d
NCT03324607 · Phase 2/3 · combination · Chronic Obstructive Pulmonary Disease · phase 2/3
show 1 more result
12.5%
NCT03081156 · Phase 4 · registry result, not featured evidence
8.3%62.5 mcge
NCT02184611 · Phase 3
show 25 more results
3%125 µg QD
NCT01772147 · Phase 3 · combination
3%62.5 µg QD
NCT01772147 · Phase 3 · combination
1%62.5 µg
NCT01957163 · Phase 3 · combination
3.4%125 µg
NCT01957163 · Phase 3 · combination
1.4%125 µg
NCT02119286 · Phase 3 · combination
3.9%62.5 µg
NCT02119286 · Phase 3 · combination
2.9%125 µg QD
NCT01772134 · Phase 3 · combination
2%62.5 µg QD
NCT01772134 · Phase 3 · combination
6%62.5/25 mcg
NCT03034915 · Phase 4 · registry result, not featured evidence
3%62.5/25 mcg
NCT02275052 · Phase 4 · registry result, not featured evidence
3.3%62.5 mcg QD
NCT02236611 · Phase 4 · registry result, not featured evidence
5%62.5 mcg+ICS/LABA
NCT02257372 · Phase 4 · registry result, not featured evidence · combination
10.4%100/62.5/25
NCT02729051 · Phase 3 · registry result, not featured evidence
3.3%62.5 mcg QD
NCT02207829 · Phase 3 · registry result, not featured evidence
4.4%62.5/25 µg
NCT02257385 · Phase 3 · registry result, not featured evidence
—62.5/25 mcg
NCT02152605 · Phase 3 · registry result, not featured evidence
6.9%62.5/25mcg
NCT02152605 · Phase 3 · registry result, not featured evidence
3.2%62.5/25 mcg
NCT01879410 · Phase 3 · registry result, not featured evidence
0.5%62.5/25 µg
NCT02014480 · Phase 3 · registry result, not featured evidence
1.7%62.5/25 µg once daily
NCT01716520 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3
0.5%100/250 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0%100/125 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0%100/15.6 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0%100/62.5 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0%100/250/25 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
Most frequent reported AEs—
62.5 mcge
upper respiratory tract infection 12.2% (placebo 12.9%)
nasopharyngitis 9.3% (placebo 10.9%)
dizziness 2.9% (placebo 2%)
NCT02184611 · Phase 3
show 23 more results
125 µg QD
nasopharyngitis 5% (placebo 4.5%)
headache 3% (placebo 4.5%)
NCT01772147 · Phase 3 · combination
62.5 µg QD
headache 4.4% (placebo 4.5%)
nasopharyngitis 3% (placebo 4.5%)
NCT01772147 · Phase 3 · combination
62.5 µg
headache 4.4% (placebo 2.9%)
back pain 3.4% (placebo 1.5%)
nasopharyngitis 3.4% (placebo 3.4%)
NCT01957163 · Phase 3 · combination
125 µg
nasopharyngitis 4.8% (placebo 3.4%)
headache 4.3% (placebo 2.9%)
cough 3.4% (placebo 0.5%)
NCT01957163 · Phase 3 · combination
125 µg
nasopharyngitis 9.2% (placebo 10.7%)
headache 1.9% (placebo 2.4%)
back pain 1% (placebo 1.9%)
NCT02119286 · Phase 3 · combination
62.5 µg
nasopharyngitis 5.3% (placebo 10.7%)
back pain 3.9% (placebo 1.9%)
headache 3.9% (placebo 2.4%)
NCT02119286 · Phase 3 · combination
125 µg QD
headache 6.3% (placebo 4.9%)
cough 2.4% (placebo 1.5%)
nasopharyngitis 2.4% (placebo 4.9%)
NCT01772134 · Phase 3 · combination
62.5 µg QD
headache 4.4% (placebo 4.9%)
cough 3.4% (placebo 1.5%)
nasopharyngitis 2.5% (placebo 4.9%)
NCT01772134 · Phase 3 · combination
62.5/25 mcg
nasopharyngitis 8.4%
NCT03034915 · Phase 4 · registry result, not featured evidence
62.5 mcg QD
headache 8.1%
nasopharyngitis 8.1%
NCT02236611 · Phase 4 · registry result, not featured evidence
62.5 mcg+ICS/LABA
nasopharyngitis 13.4% (placebo 14.5%)
headache 3.4% (placebo 6.8%)
cough 2.5% (placebo 4.3%)
NCT02257372 · Phase 4 · registry result, not featured evidence · combination
100/62.5/25
viral upper respiratory tract infection 10.6%
headache 6.1%
upper respiratory tract infection 3.4%
NCT02729051 · Phase 3 · registry result, not featured evidence
62.5 mcg QD
headache 5.9%
nasopharyngitis 5.3%
NCT02207829 · Phase 3 · registry result, not featured evidence
62.5/25 µg
headache 7.5%
nasopharyngitis 6.6%
cough 3.3%
NCT02257385 · Phase 3 · registry result, not featured evidence
62.5/25mcg
headache 6.5% (placebo 6.5%)
nasopharyngitis 5.2% (placebo 6.5%)
NCT02152605 · Phase 3 · registry result, not featured evidence
62.5/25 mcg
headache 6.9%
nasopharyngitis 4%
NCT01879410 · Phase 3 · registry result, not featured evidence
62.5/25 µg
headache 5%
NCT02014480 · Phase 3 · registry result, not featured evidence
62.5/25 µg once daily
nasopharyngitis 4%
headache 3.5%
NCT01716520 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3
100/250 µg
nasopharyngitis 1.9%
toothache 0.5%
dysphonia 0%
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
100/125 µg
dysphonia 6.5%
nasopharyngitis 4.3%
toothache 0%
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
100/15.6 µg
nasopharyngitis 7.1%
toothache 7.1%
dysphonia 0%
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
100/62.5 µg
nasopharyngitis 5%
dysphonia 2.5%
toothache 2.5%
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
100/250/25 µg
dysphonia 0%
nasopharyngitis 0%
toothache 0%
NCT02164539 · Phase 2 · registry result, not featured evidence · combination

Notes

  1. aPopulation comparability has not been reviewed for both studies.
  2. bTreatment context has not been resolved for both arms.
  3. cThe assessment timepoint is not available for both results.
  4. dPopulation comparability has not been reviewed for 1 of these studies.
  5. ePopulation comparability has not been reviewed for 25 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Glycopyrrolate/formoterol fumarate

FVC 0.342 L @ 2wk
absolute change · L
No placebo or comparator arm
NCT03324607 · Phase 2/3 · combination · Chronic Obstructive Pulmonary Disease · phase 2/3 · converted to L from 342 mL as posted
FEV1 0.219 L @ 2wk
absolute change · L
No placebo or comparator arm
NCT03324607 · Phase 2/3 · combination · Chronic Obstructive Pulmonary Disease · phase 2/3 · converted to L from 219 mL as posted
Six Minute Walk 16.2 m @ 2wk
absolute change · m
No placebo or comparator arm
NCT03324607 · Phase 2/3 · combination · Chronic Obstructive Pulmonary Disease · phase 2/3
SGRQ Total -1.2 score @ 2wk
absolute change · score
No placebo or comparator arm
NCT03324607 · Phase 2/3 · combination · Chronic Obstructive Pulmonary Disease · phase 2/3
RPD -0.75 score @ 2wk
absolute change · score
No placebo or comparator arm
NCT03324607 · Phase 2/3 · combination · Chronic Obstructive Pulmonary Disease · phase 2/3

Umeclidinium

FEV1 Trough 0.131 vs -0.022 placebo L @ 24wk62.5 mcg
absolute change · L
NCT02184611 · Phase 3
show 21 more results
0.103 vs -0.02 placebo L @ 12.14wk62.5 µg
NCT01957163 · Phase 3 · combination
0.122 vs 0.056 UMEC L @ 24wk62.5/25 mcg
NCT03034915 · Phase 4 · registry result, not featured evidence
0.173 vs -0.034 placebo L @ 12wk62.5/25 mcg
NCT02275052 · Phase 4 · registry result, not featured evidence
0.123 vs 0.099 GLYCO L @ 12wk62.5 mcg QD
NCT02236611 · Phase 4 · registry result, not featured evidence
0.09 vs -0.033 placebo L @ 12wk62.5 mcg+ICS/LABA
NCT02257372 · Phase 4 · registry result, not featured evidence · combination
0.154 vs 0.095 Tiotropium L @ 12.14wk62.5 mcg QD
NCT02207829 · Phase 3 · registry result, not featured evidence
0.172 vs 0.171 Indacaterol + Tiotropium Bromide L @ 12.14wk62.5/25 µg
NCT02257385 · Phase 3 · registry result, not featured evidence
0.152 vs 0.03 placebo L @ 12wk62.5/25 mcg
NCT02152605 · Phase 3 · registry result, not featured evidence
0.185 vs 0.087 FSC L @ 12.14wk62.5/25 mcg
NCT01879410 · Phase 3 · registry result, not featured evidence
0.147 vs -0.001 placebo L @ 12.14wk125 µg QD
NCT01772147 · Phase 3 · combination
0.108 vs -0.02 placebo L @ 12.14wk125 µg
NCT01957163 · Phase 3 · combination
0.116 vs -0.022 placebo L @ 12wk125 µg QD
NCT01772134 · Phase 3 · combination
0.126 vs -0.001 placebo L @ 12.14wk62.5 µg QD
NCT01772147 · Phase 3 · combination
0.125 vs -0.022 placebo L @ 12wk62.5 µg QD
NCT01772134 · Phase 3 · combination
0.143 vs 0.047 FF L @ 4wk100/250 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0.081 vs -0.03 placebo L @ 12.14wk125 µg
NCT02119286 · Phase 3 · combination
0.175 vs 0.047 FF L @ 4wk100/125 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0.146 vs 0.047 FF L @ 4wk100/15.6 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0.193 vs 0.047 FF L @ 4wk100/62.5 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
0.092 vs -0.03 placebo L @ 12.14wk62.5 µg
NCT02119286 · Phase 3 · combination
0.113 vs 0.095 FF/VI + UMEC L @ 24wk100/62.5/25
NCT02729051 · Phase 3 · registry result, not featured evidence
TDI Focal 2.5 vs 1.6 placebo score @ 24wk62.5 mcg
absolute change · score
NCT02184611 · Phase 3
FEV1 Wm0 6 h 0.136 vs 0.011 placebo L @ 0wk62.5 mcg
absolute change · L
NCT02184611 · Phase 3
show 10 more results
0.187 vs 0.034 placebo L @ 12wk62.5 µg
NCT01957163 · Phase 3 · combination
0.184 vs 0.035 placebo L @ 12wk62.5 mcg+ICS/LABA
NCT02257372 · Phase 4 · registry result, not featured evidence · combination
0.235 vs 0.258 Indacaterol + Tiotropium Bromide L @ 12wk62.5/25 µg
NCT02257385 · Phase 3 · registry result, not featured evidence
0.217 vs 0.052 placebo L @ 12wk125 µg QD
NCT01772147 · Phase 3 · combination
0.175 vs 0.034 placebo L @ 12wk125 µg
NCT01957163 · Phase 3 · combination
0.192 vs 0.032 placebo L @ 12wk125 µg QD
NCT01772134 · Phase 3 · combination
0.196 vs 0.052 placebo L @ 12wk62.5 µg QD
NCT01772147 · Phase 3 · combination
0.196 vs 0.032 placebo L @ 12wk62.5 µg QD
NCT01772134 · Phase 3 · combination
0.152 vs 0.017 placebo L @ 12wk125 µg
NCT02119286 · Phase 3 · combination
0.164 vs 0.017 placebo L @ 12wk62.5 µg
NCT02119286 · Phase 3 · combination
SGRQ Total -5.84 vs -1.45 placebo score @ 4wk62.5 mcg
absolute change · score
NCT02184611 · Phase 3
show 5 more results
-7.05 vs -2.46 placebo score @ 12wk62.5 mcg
NCT02184611 · Phase 3
-7.34 vs -4.31 placebo score @ 24wk62.5 mcg
NCT02184611 · Phase 3
-4.98 vs -5.23 UMEC score @ 24wk62.5/25 mcg
NCT03034915 · Phase 4 · registry result, not featured evidence
-6.15 vs -2.12 placebo score @ 12wk62.5/25 mcg
NCT02152605 · Phase 3 · registry result, not featured evidence
-5.841 vs -4.935 FF/VI + UMEC score @ 24wk100/62.5/25
NCT02729051 · Phase 3 · registry result, not featured evidence
CAT Total -1.75 vs -0.26 placebo score @ 4wk62.5 mcg
absolute change · score
NCT02184611 · Phase 3
show 2 more results
-2.18 vs -0.08 placebo score @ 12wk62.5 mcg
NCT02184611 · Phase 3
-2 vs -1.32 placebo score @ 24wk62.5 mcg
NCT02184611 · Phase 3
Rescue-free 24-h Period 15.2 vs 1.9 placebo % of time @ 12wk125 µg QD
percent change · % of time
NCT01772147 · Phase 3 · combination
show 1 more result
8.4 vs 1.9 placebo % of time @ 12wk62.5 µg QD
NCT01772147 · Phase 3 · combination
Rescue Puffs -0.7 vs -0.2 placebo puffs @ 12wk125 µg QD
absolute change · puffs
NCT01772147 · Phase 3 · combination
show 3 more results
-0.5 vs -0.2 placebo puffs @ 12wk125 µg QD
NCT01772134 · Phase 3 · combination
-0.4 vs -0.2 placebo puffs @ 12wk62.5 µg QD
NCT01772147 · Phase 3 · combination
-0.5 vs -0.2 placebo puffs @ 12wk62.5 µg QD
NCT01772134 · Phase 3 · combination
Rescue-free 24 h Periods 11.1 vs 4.9 placebo % of time @ 12wk125 µg QD
absolute change · % of time
NCT01772134 · Phase 3 · combination
show 1 more result
13.3 vs 4.9 placebo % of time @ 12wk62.5 µg QD
NCT01772134 · Phase 3 · combination
TDI Focal 1.68 vs 1.3 UMEC score @ 24wk62.5/25 mcg
absolute value · score
NCT03034915 · Phase 4 · registry result, not featured evidence
TDI Focal 50% (n=806) vs 42% (n=799) UMEC @ 24wk62.5/25 mcg
responder rate · % of participants
NCT03034915 · Phase 4 · registry result, not featured evidence
show 1 more result
56% (n=482) vs 56% (n=481) FF/VI + UMEC @ 24wk100/62.5/25
NCT02729051 · Phase 3 · registry result, not featured evidence
E-RS Total -1.52 vs -0.99 UMEC score @ 24wk62.5/25 mcg
absolute change · score
NCT03034915 · Phase 4 · registry result, not featured evidence
show 4 more results
-1.5 vs 0.5 FF score @ 4wk100/250 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
-1.5 vs 0.5 FF score @ 4wk100/125 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
-2.6 vs 0.5 FF score @ 4wk100/15.6 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
-2.5 vs 0.5 FF score @ 4wk100/62.5 µg
NCT02164539 · Phase 2 · registry result, not featured evidence · combination
E-RS Cough Sputum Domain -0.45 vs -0.38 UMEC score @ 24wk62.5/25 mcg
absolute change · score
RS-CSP
NCT03034915 · Phase 4 · registry result, not featured evidence

+ 14 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Glycopyrrolate/formoterol fumarate's landscape · Umeclidinium's landscape